BLASUBCUTANEOUSSOLUTION
Approved
May 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
13
Data completeness
5/8 — Partial
Cutaquig (immunoglobulin g) by Octapharma is (igg) antibodies against a wide variety of bacterial and viral agents. Approved for kawasaki disease, primary immunodeficiency. First approved in 2019.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Cutaquig is a subcutaneous immunoglobulin G (IgG) solution approved in 2019 that provides antibodies against bacterial and viral pathogens. It restores abnormally low IgG levels to normal range in primary immunodeficiency and treats multiple autoimmune and infectious conditions. The mechanism involves antigen neutralization and immune reconstitution across a broad spectrum of indications.
$2MPart D
PeakProduct is at peak lifecycle with modest Part D utilization (254 claims) and minimal commercial scale, suggesting limited brand team expansion but stable maintenance phase operations.
Mechanism of Action
(IgG) antibodies against a wide variety of bacterial and viral agents. It has a distribution of immune globulin subclasses closely proportional to that in native human plasma. The mechanism of action in primary humoral immunodeficiency (PI) has not been fully elucidated; however adequate doses may…
Pharmacologic Class:
Antigen Neutralization
Indications (2)
Worked on Cutaquig at Octapharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.